Global Oncology Biosimilars Market was valued at USD 4.00 billion in 2021 and is expected to reach USD 15.55 billion by 2029, registering a CAGR of 18.5% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework. A biosimilar is a biological product that closely mimics and is identical to a previously approved reference product. These are less expensive than branded or certified items. Several oncology biologics have already lost their patents, and others are about to expire. Biosimilars are predicted to gain popularity as more products lose their patents. Leading generic companies including Allergan Plc., Teva Pharmaceutical Industries Ltd., Mylan N.V., and Sandoz (a Novartis International AG division) are likely to benefit from these patent expirations and position themselves as market leaders in oncology biosimilars.

Get a Sample PDF of Oncology Biosimilars Market report - https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-oncology-biosimilars-market

Oncology Biosimilars Market Leading Key Players:

  • Pfizer Inc. (U.S.)
  • GlaxoSmithKline plc (U.K.)
  • Novartis AG (Switzerland)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd.(Israel)
  • Sanofi (France)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Zydus Cadila (India)
  • Lupin (India)
  • Amneal Pharmaceuticals LLC. (U.S.)
  • Cipla Inc. (U.S.)
  • Aurobindo Pharma (India)
  • Glenmark Pharmaceuticals Limited (India)
  • Eli Lilly and Company (U.S.)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Allergan (Ireland)
  • Bristol-Myers Squibb Company (U.S.)
  • Takeda Pharmaceutical Company Limited (Japan)
  • BIOCAD (Russia)
  • Apotex Inc. (Canada)
  • Endo International plc (Ireland)

 

Global Oncology Biosimilars Market Scenario:

This Oncology Biosimilars market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Oncology Biosimilars market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Oncology Biosimilars Market Dynamics

Drivers

  • Rise in the prevalence of cancer

The surging prevalence of cancer is a major factor driving the oncology biosimilars market's growth rate during the forecast period of 2022-2029. Cancer is a lifestyle disease caused by abnormal cell proliferation that can lead to the formation of a tumor. Biological medications, often known as biologics, are used in the majority of effective cancer treatments nowadays, including targeted therapies and immunotherapies. These medications are derived from living creatures such as bacteria, animal or plant cells, yeast and they require complicated manufacturing techniques and a long development time. The development of biosimilars of branded cancer biologics is gaining popularity as a way to reduce treatment costs.

  • Growing number of government initiatives

The rising initiatives by government is expected to expand the oncology biosimilars market. Additionally, Biosimilars are being promoted by governments in a number of nations as a cost-cutting solution. The United States Food and Drug Administration (USFDA), for instance, has created educational materials for physicians and patients on biosimilars.

Furthermore, sedentary lifestyle of people and surging geriatric population will result in the expansion of oncology biosimilars market. Along with this, rising healthcare expenditure and increasing demand for biosimilar drugs due to their cost-effectiveness will enhance the growth rate of the market.

Opportunities

  • Increase in the number of research and development activities      

The rising number of research and development activities for new indications and patent expiry of biologics is estimated to create new opportunities for the oncology biosimilars market growth in coming years. The players are investing in these research activities in order to test different formulas and increase revenue. The competitors also engage in strategic alliances, which aid in significantly affecting the oncology biosimilars market's growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the oncology biosimilars market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost associated with the drug development and distribution will obstruct the growth rate of market. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the oncology biosimilars market. Additionally, regulatory as well as clinical barriers and resistance from biologics manufacturers will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This oncology biosimilars market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the oncology biosimilars market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Oncology biosimilars market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

To Gain More Insights into the Oncology Biosimilars Market Analysis, Browse Summary of the Research Report@ https://www.databridgemarketresearch.com/reports/global-oncology-biosimilars-market

Global Oncology Biosimilars Market Scope and Market Size

The Oncology Biosimilars market is segmented on the basis of indication, drug class, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Blood Cancer
  • Others

Drug Class

Route of Administration

  • Intravenous
  • Subcutaneous
  • Others

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Oncology Biosimilars Market Country Level Analysis

The Oncology Biosimilars market is analyzed and market size insights and trends are provided by country, type, deployment and end user pas referenced above.    

The countries covered in the Oncology Biosimilars market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the Oncology Biosimilars market because of the presence of favorable regulatory scenario and high adoption of HCIT solutions within the region. Asia-Pacific is expected to witness significant growth during the forecast period of 2022 to 2029 due to the presence of a large number of healthcare IT companies in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

 Browse the complete table of contents at Oncology Biosimilars Market - https://www.databridgemarketresearch.com/toc/?dbmr=global-oncology-biosimilars-market

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The Oncology Biosimilars market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Oncology Biosimilars market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Oncology Biosimilars market. The data is available for historic period 2010-2020.

Competitive Landscape and Oncology Biosimilars Market Share Analysis

The Oncology Biosimilars market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Oncology Biosimilars market.

Report Coverage:

  • Major growth drivers, restraining factors, opportunities, and potential challenges for the market.
  • Comprehensive insights into the regional developments.
  • List of major industry players.
  • Key strategies adopted by the market players.
  • Latest industry developments include product launches, partnerships, mergers, and acquisitions.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global & Regional Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the analyst's Proprietary competitive positioning tool.

Top Healthcare Report:

Global Teleradiology Market – Industry Trends and Forecast to 2028

Asia-Pacific TelOncology Biosimilars Market – Industry Trends and Forecast to 2029

Global Mobile Cardiac Telemetry (MCAT) Market – Industry Trends and Forecast to 2028

Middle East and Africa Mobile Cardiac Telemetry (MCT) Market - Industry Trends and Forecast to 2028

North America Mobile Cardiac Telemetry (MCT) Market - Industry Trends and Forecast to 2028

About Data Bridge Market Research, Private Ltd

Data Bridge Market Research Pvt Ltd is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. “Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.”

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[email protected]